Literature DB >> 15297972

Heterogeneity of genomic breakpoints in MSN-ALK translocations in anaplastic large cell lymphoma.

Frederic Tort1, Elias Campo, Brad Pohlman, Eric Hsi.   

Abstract

Anaplastic large cell lymphomas (ALCL) are associated with the t(2;5)(p23;q35) translocation involving the anaplastic lymphoma kinase (ALK) and the nucleophosmin (NPM) genes. However, genes other than NPM may fuse to ALK in these tumors. In this study we have identified an ALCL with a distinctive cell membrane-restrictive ALK immunostaining in which the molecular characterization showed a new fusion gene between moesin (MSN) and ALK with different breakpoints than previously recognized. The ALK breakpoint occurred in an exonic sequence, and the chimeric gene included an intronic sequence of MSN. Identification of the genomic breakpoint in the derivative chromosome 2 revealed a 72-base pair deletion involving both MSN and ALK sequences. These findings provide further evidence of the breakpoint heterogeneity in ALK translocations and highlight the importance of ALK immunostaining in the diagnosis of ALCL and the identification of the underlying genetic abnormalities in this lymphoma.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15297972     DOI: 10.1016/j.humpath.2004.05.006

Source DB:  PubMed          Journal:  Hum Pathol        ISSN: 0046-8177            Impact factor:   3.466


  9 in total

Review 1.  Anaplastic large cell lymphoma: pathology, genetics, and clinical aspects.

Authors:  Naoko Tsuyama; Kana Sakamoto; Seiji Sakata; Akito Dobashi; Kengo Takeuchi
Journal:  J Clin Exp Hematop       Date:  2017

2.  Reliability analysis of exonic-breakpoint fusions identified by DNA sequencing for predicting the efficacy of targeted therapy in non-small cell lung cancer.

Authors:  Weihua Li; Rui Wan; Lei Guo; Geyun Chang; Dong Jiang; Lin Meng; Jianming Ying
Journal:  BMC Med       Date:  2022-05-10       Impact factor: 11.150

3.  Fusion of EML4 and ALK is associated with development of lung adenocarcinomas lacking EGFR and KRAS mutations and is correlated with ALK expression.

Authors:  Xuchao Zhang; Shirley Zhang; Xuening Yang; Jinji Yang; Qing Zhou; Lucy Yin; Shejuan An; Jiaying Lin; Shiliang Chen; Zhi Xie; Mike Zhu; Xiaolin Zhang; Yi-long Wu
Journal:  Mol Cancer       Date:  2010-07-13       Impact factor: 27.401

Review 4.  Fusion genes and their discovery using high throughput sequencing.

Authors:  M J Annala; B C Parker; W Zhang; M Nykter
Journal:  Cancer Lett       Date:  2013-01-29       Impact factor: 8.679

5.  ALK Signaling and Target Therapy in Anaplastic Large Cell Lymphoma.

Authors:  Fabrizio Tabbó; Antonella Barreca; Roberto Piva; Giorgio Inghirami
Journal:  Front Oncol       Date:  2012-05-11       Impact factor: 6.244

6.  Pediatric T- and NK-cell lymphomas: new biologic insights and treatment strategies.

Authors:  N K El-Mallawany; J K Frazer; P Van Vlierberghe; A A Ferrando; S Perkins; M Lim; Y Chu; M S Cairo
Journal:  Blood Cancer J       Date:  2012-04-13       Impact factor: 11.037

Review 7.  Novel ALK inhibitors in clinical use and development.

Authors:  Chaitanya Iragavarapu; Milaim Mustafa; Akintunde Akinleye; Muhammad Furqan; Varun Mittal; Shundong Cang; Delong Liu
Journal:  J Hematol Oncol       Date:  2015-02-27       Impact factor: 17.388

8.  Multi-dimensional genomic analysis of myoepithelial carcinoma identifies prevalent oncogenic gene fusions.

Authors:  Martin G Dalin; Nora Katabi; Marta Persson; Ken-Wing Lee; Vladimir Makarov; Alexis Desrichard; Logan A Walsh; Lyndsay West; Zaineb Nadeem; Deepa Ramaswami; Jonathan J Havel; Fengshen Kuo; Kalyani Chadalavada; Gouri J Nanjangud; Ian Ganly; Nadeem Riaz; Alan L Ho; Cristina R Antonescu; Ronald Ghossein; Göran Stenman; Timothy A Chan; Luc G T Morris
Journal:  Nat Commun       Date:  2017-10-30       Impact factor: 14.919

Review 9.  Tumor Resistance against ALK Targeted Therapy-Where It Comes From and Where It Goes.

Authors:  Geeta Geeta Sharma; Ines Mota; Luca Mologni; Enrico Patrucco; Carlo Gambacorti-Passerini; Roberto Chiarle
Journal:  Cancers (Basel)       Date:  2018-02-28       Impact factor: 6.639

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.